Overview

Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Status:
Active, not recruiting

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

This study evaluates a new treatment combination of ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory multiple myeloma. Participants will either receive ixazomib with cyclophosphamide and dexamethasone or cyclophosphamide and dexamethasone alone.

Phase:

Phase 2

Details

Lead Sponsor:

University of Leeds

Collaborators:

Millennium Pharmaceuticals, Inc.
Myeloma UK

Treatments:

BB 1101
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Glycine
Ixazomib